Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):323-34. doi: 10.1016/j.clml.2015.03.006. Epub 2015 Mar 24.

Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.

Author information

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.


Although imatinib remains the gold standard for first-line treatment of chronic myeloid leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the development of additional tyrosine kinase inhibitors (TKIs), which have demonstrated effectiveness as salvage therapies or alternative first-line treatments. Although additional options represent progress, the availability of 3 second-generation TKIs (dasatinib, nilotinib, and bosutinib) and 1 third-generation TKI (ponatinib) has added complexity to the treatment paradigm for CML, particularly CML in the chronic phase. Two second-generation agents (dasatinib and nilotinib) are approved for use as first-line and subsequent therapy. Thus, the appropriate sequencing of TKIs is a frequent quandary, and is incompletely addressed in clinical guidelines. Here, we review studies that might guide selection of a second- or third-generation TKI after failure of TKI therapy in patients with chronic-phase CML. These studies evaluate prognostic factors such as first-line cytogenetic response and BCR-ABL1 mutation status, which might help physicians identify patients who are likely to respond to second-generation TKIs, and those for whom ponatinib or an investigational agent might be more appropriate. We summarize evidence to date that suggests that use of a second-generation TKI as third-line therapy confers limited value in most CML patients, and we also explore the utility of current event-free survival versus traditional outcomes to predict long-term benefits of sequential TKI use. Finally, we present 3 case studies to illustrate how prognostic factors and other considerations (eg, tolerability) can be used to individualize subsequent therapy in cases of TKI resistance or intolerance.


BCR-ABL1; Outcome; Prognosis; Resistance; Response

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Dr Jabbour has received honoraria from ARIAD Pharmaceuticals, Inc., Pfizer, Bristol-Myers Squibb, Novartis, and Teva, outside the submitted work; Dr Kantarjian has received research grants from Novartis, Bristol-Myers Squibb, Pfizer, and ARIAD Pharmaceuticals, Inc., outside the submitted work; Dr Cortes reports grants and personal fees for consulting from ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb, Novartis, Pfizer, and Teva, outside the submitted work.

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center